Arkansas Children’s Hospital has inked an agreement with magnetoencephalography (MEG) technology provider MEGIN to acquire and install its TRIUX neo MEG system for functional brain imaging.
Designed as a non-invasive diagnostic device, MEG is used to measure magnetic activity produced by neurons in the brain.
Go deeper with GlobalData
Owing to its ability to detect and localise neural events with millimetre accuracy and millisecond resolution, TRIUX neo is used in the detection and evaluation of complex neurological disruptions.
MEGIN said that the detection capability is effective for the diagnosis of epilepsy, post-traumatic stress disorder, brain tumours, traumatic brain injury, and autism.
TRIUX neo is planned to be installed by the end of this year.
Arkansas Children’s Hospital neurology chief Gregory Sharp said: “MEG is a state-of-the-art device that can precisely localise the source of seizures within the brain to help provide a life-changing cure for select children with uncontrolled epilepsy. This asset will lead to new understandings of neurologic disorders through research.”
MEGIN CEO Janne Huhtala added: “We are very excited to be working with Arkansas Children’s Hospital and providing our latest technology in functional brain imaging for their patients.
“The information gained through the use of MEG can have a significant impact on patients who are otherwise left with few definitive answers when faced with surgery.”
Arkansas Children’s Hospital is a 336-bed hospital in Little Rock, equipped with the paediatric Level 1 Trauma Centre, burn centre, Level 4 neonatal intensive care and paediatric intensive care, as well as research institute.
